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Abstract
Background: There are numerous methods for adjusting measured concentrations of urinary biomarkers for
hydration variation. Few studies use objective criteria to quantify the relative performance of these methods. Our
aim was to compare the performance of existing methods for adjusting urinary biomarkers for hydration variation.
Methods: Creatinine, osmolality, excretion rate (ER), bodyweight adjusted ER (ERBW) and empirical analyte-specific
urinary flow rate (UFR) adjustment methods on spot urinary concentrations of lead (Pb), cadmium (Cd),
non-arsenobetaine arsenic (AsIMM) and iodine (I) from the US National Health and Nutrition Examination Survey
(NHANES) (2009–2010 and 2011–2012) were evaluated. The data were divided into a training dataset (n = 1,723)
from which empirical adjustment coefficients were derived and a testing dataset (n = 428) on which quantification
of the performance of the adjustment methods was done by calculating, primarily, the correlation of the adjusted
parameter with UFR, with lower correlations indicating better performance and, secondarily, the correlation of the
adjusted parameters with blood analyte concentrations (Pb and Cd), with higher correlations indicating better
performance.
Results: Overall performance across analytes was better for Osmolality and UFR based methods. Excretion rate and
ERBW consistently performed worse, often no better than unadjusted concentrations.
Conclusions: Osmolality adjustment of urinary biomonitoring data provides for more robust adjustment than either
creatinine based or ER or ERBW methods, the latter two of which tend to overcompensate for UFR. Modified UFR
methods perform significantly better than all but osmolality in removing hydration variation, but depend on the
accuracy of UFR calculations. Hydration adjustment performance is analyte-specific and further research is needed
to establish a robust and consistent framework.
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Background
Urinary biomonitoring is the preferred method of exposure
and nutritional assessment for many chemical elements
and metabolites given its non-invasiveness, logistical ap-
peal and ease of measurement with modern analytical
techniques [1]. This is true for potentially harmful ele-
ments like arsenic (As) [2], essential nutrients like iodine
(I) [3] and drug and organic compounds [4, 5], making the
meaningful interpretation of urinary data a requirement
with implications for public health, occupational health
and forensic applications. The US National Health and
Nutrition Examination Survey (NHANES) has proved an
invaluable, growing resource of chemical biomonitoring
data [6], but the value of such data depend on their
correct interpretation [7], challenges with which are
currently limiting the full potential of urinary chemical
biomarkers [6].
Urinary analyte concentrations are susceptible to vari-
ation from factors extending beyond exposure and are
categorised [1] as follows: (i) time of sampling relative to
exposure; (ii) inter-individual toxico-kinetic factors and
(iii) physiological characteristics of the biomonitoring
matrix. While the first two factors should not be ig-
nored, the third, specifically the variation in dilution
among spot urine samples, is addressed here.
While collection of 24 hr urine samples is preferred, it
is not feasible for large biomonitoring studies due to re-
source limitations, cumbersome sample nature and vol-
unteer compliance issues [8]. First morning void (FMV)
or spot collections are common substitutes, but are lim-
ited in that they reflect the hydration status of the indi-
vidual at the time of collection thus may differ markedly
in dilution as a result of differences in urinary flow rate
(UFR). Spot/FMV samples are nevertheless widely deemed
acceptable provided that the effect of sample dilution is
quantified and appropriately adjusted [9]. Several methods
for adjusting spot/FMV data are currently employed but
there is no consensus on which is the most appropriate.
The most common technique employed is creatinine
adjustment, whereby urinary analyte concentrations are
ratioed to creatinine concentrations. This method impli-
citly assumes that urinary creatinine is excreted at a
constant rate and varies only as a function of UFR. How-
ever, these assumptions are of questionable validity,
since creatinine concentrations have been shown to de-
pend upon all of demographic group [10], protein intake
[11], muscle mass [12] and malnutrition [13].
Alternative methods such as specific gravity (SG) or
osmolality adjustment are commonly reported. Close
agreement has been demonstrated between these methods
[14] but osmolality, as measured by osmometry, has been
described as the definitive measure of urinary concentra-
tion [15] despite being previously considered prohibitively
expensive [16]. Osmometry is not susceptible to the same
interferences as SG, conventionally measured by refract-
ometry, which may be confounded in subjects with, for
example, proteinuria and glucosuria. Urinary osmolality
was a post-2008 inclusion in NHANES and, while similar
factors affecting creatinine excretion were found to be re-
sponsible for variation in urinary osmolality, less influence
was observed on osmolality than on creatinine in the US
population [8].
Creatinine, SG and osmolality are all surrogate estima-
tors of UFR with various degrees of effectiveness [17, 18].
Direct UFR measurements are now included in post-2008
NHANES cycles, with UFR determined as follows:
UFR ¼ V=t; ð1Þ
where t is the time elapsed between two urine voids
and V is the volume of the second void. Excretion
rates (ER), typically expressed in ng/hr, of the analyte
can be calculated:
ER ¼ Cvol  Vð Þ=t; ð2Þ
where Cvol is the measured, volume-based urinary ana-
lyte concentration, typically in nanograms per millilitre,
V is volume, typically in millilitres and t is time, typically
in hours. Additionally, bodyweight (BW) adjusted ER
(ERBW), typically expressed in ng/kg-hr, can be calculated
as follows:
ERBW ¼ Cvol  Vð Þ= t  BWð Þ: ð3Þ
Adjusting urinary biomonitoring results according to
Eqs. 2 and 3 was recently proposed to directly account
for hydration status and address demographic variations
in UFR more effectively than creatinine and osmolality
adjustments [19]. While UFR, providing accurate meas-
urement of time and volume, is more reflective of hydra-
tion status than surrogate measures, such as creatinine
and osmolality, its application in Eqs. 2 and 3 directly incor-
porates hydration bias into results. Given that ERs can still
apply to restricted time periods, they are dependent on
UFR, i.e. hydration, at that time. Strong positive Spearman’s
correlation coefficients (rs) have been reported between
ERs of urinary analytes and UFR [20, 21], indicating that
the adjustment in Eq. 2 is not theoretically robust.
Specifically, application of Eq. 2 implicitly assumes that
analyte concentrations vary inversely proportionally with
UFR. However, this was disputed by Araki et al. (1990),
who observed analyte-specific, log-linear relationships be-
tween analyte concentrations and UFR of the form:
log Cvol ¼ a−b log UFR; ð4Þ
where a and b (referred to here as Araki’s b value)
are analyte-dependent, empirically determined regres-
sion coefficients.
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Araki et al. (1990) therefore proposed a modified UFR
adjustment whereby analyte concentrations were ad-
justed to a standard UFR of 1 mL/min:
CUFR‐adj ¼ Cvol  UFRb; ð5Þ
where Araki’s b values were derived for a number of ana-
lytes using multiple voids from single individuals sub-
jected to water loading and water restrictive conditions.
This UFR adjustment was found to be more effective
than ER, creatinine and SG adjustment in removing
UFR-dependent variation from adjusted urinary analyte
concentrations [20, 21]. For datasets, such as NHANES,
that do not contain extensive analyte concentration data
for multiple voids from single individuals, a previously
reported iterative method [22] may be used to calculate
population-level Araki’s b values by optimising appropri-
ate performance criteria.
Comparing the performance of urinary hydration ad-
justment methods requires assessment criteria appropri-
ate to the needs of a given study. Suggested criteria are
summarised in Table 1. For this work, the primary as-
sessment criterion was the extent of removal of system-
atic dependence on UFR of adjusted urinary analyte
concentrations (Criterion A, Table 1) as has been used
previously [20, 22, 23]. Additionally, since blood bio-
monitoring is the preferred measure of exposure for
several chemicals, notably lead (Pb), and is not as sus-
ceptible to the same level of variation as urinary concen-
trations [24], the correlation between adjusted urinary
concentrations and blood concentrations was also used
as a secondary assessment criterion (Criterion B, Table 1)
and has been previously explored [25] for Pb. Similarly,
in the case of cadmium (Cd), blood is a biomarker of
both recent and cumulative Cd exposure, and urinary
concentrations reflect cumulative exposures and Cd
levels in the kidney [26]. Agreement between urinary
and blood Cd concentrations have been reported [27],
making it reasonable to hypothesize that the effective re-
moval of hydration variation from spot urine samples
may strengthen this relationship. Other possible assess-
ment criteria include agreement with 24 hr excretion
rates or composite concentrations, used previously [14],
but the lack of 24 hr data in the NHANES survey does
not permit this. Lastly, an independent external measure
of exposure, e.g. drinking water analyte concentrations
[28] could be used as an assessment criterion, but was
not used in this study because of a lack of appropriate
environmental data in NHANES.
Methods
Aims
This paper aims to compare the performance of urinary
biomonitoring hydration adjustment techniques using
NHANES (2009–2010, 2011–2012) spot urinary concen-
trations of selected chemical analytes and, in particular,
test whether or not analyte-specific UFR adjusted con-
centrations provide a more robust adjustment than cre-
atinine, osmolality, ER or ERBW adjustments. Arsenic
and iodine were selected as chemicals on which to make
these tests as respectively toxic and essential elements
for which urinary biomonitoring is widely used. Addition-
ally, Pb and Cd were selected for study, due to the avail-
ability of paired urine-blood samples in the NHANES
database and the applicability of criterion B to these ele-
ments. This provides the opportunity to compare the ad-
justment performance characteristics of two independent
assessment criteria.
Data acquisition
Data from the NHANES 2009–2010 and 2011–2012 sur-
veys were acquired from the NHANES website [29].
Volunteer consent information and dataset access can
be found online: http://www.cdc.gov/nchs/nhanes.htm.
Data on demographic variables; body measurements;
standard biochemistry profile; diabetes; kidney condi-
tions; plasma fasting glucose; urinary flow rates; urinary
creatinine; urinary osmolality; urinary metals; total and
speciation urinary As; urinary I and blood metals were
downloaded in SAS (.xpt) format. Data were converted
to MS Excel (.xlsx) format using the R programming en-
vironment SASxport and xlsx packages [30, 31], before
being matched by sequence number (SQN) in MS Ac-
cess. Volunteers with data present on gender, age, body-
weight, urinary creatinine, urinary osmolality, UFR, As
speciation and blood metals, of either non-Hispanic
Table 1 Suggested criteria for assessing performance of urinary biomonitoring adjustment methods
Criterion Description Performance metric
A Correlation between adjusted spot analyte concentrations and UFR. Weaker correlations indicating good performance.
B Correlation between adjusted spot analyte concentration and an independent
measure of internal dose, e.g. analyte concentration in blood.
Stronger correlations indicating good performance.
C Correlation of spot analyte concentrations with analyte excretion over 24 hr
or composite 24 hr concentrations.
Closer agreement/lower variation in spot samples
indicating good performance.
D Correlation of spot analyte concentration with an independent measure of/proxy
for external exposure e.g. drinking water analyte concentration.
Stronger correlations indicating good performance.
Criteria A and B are used in this study
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white, non-Hispanic black or Mexican American ethni-
city were initially included.
Volunteers with evidence of health conditions that
could affect the performance of urinary adjustment cal-
culations were excluded using previously published cri-
teria [10, 19]: urinary albumin-creatinine ratio >30 mg/g
creatinine was treated as albuminuria and diabetics were
identified by self-reported physician diagnosis or plasma
glucose ≥126 mg/dL (≥8 h fasting) or ≥200 mg/dL (<8 h
fasting). Chronic kidney disease (CKD) was identified by
self-reported physician diagnosis or an estimated glom-
erular filtration rate (eGFR) <60 mL/min/1.73 m2 using
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [32]. For volunteers aged <18, eGFR
was estimated using the Bedside Schwartz equation [33].
Finally, volunteers without detectable concentrations of
urinary Pb, Cd, Total As and I were excluded to limit
the effects of censoring on analyses.
Additional data from a single volunteer consisting of
multiple spot Cd concentrations and UFR measurements
were reproduced [34] for observational purposes only.
Analytical measurements
Detailed analytical methodologies for the analytes inves-
tigated in this paper, plus other analytical components of
NHANES, are reported online: http://www.cdc.gov/nchs/
nhanes/nhanes2011-2012/lab_methods_11_12.htm. Urine
samples were provided by volunteers at the NHANES mo-
bile examination center (MEC). Volunteers were asked to
fully void the bladder and report the last time of previ-
ously doing so. Volumes of the samples provided at the
MEC were measured and used, with the previous void
times reported by volunteers, to calculate UFR as per
Eq. 1. For volunteers with initial urinary volumes below
requirement, subsequent voids were collected and com-
posite UFRs were calculated using the total volumes and
times covered by all voids. This ensured that laboratory
measurements made on pooled samples consisting of
multiple voids corresponded to the correct UFRs. Urinary
osmolality was measured using freezing-point depression
(cryoscopic) osmometry performed with an Osmette II,
Model 5005 Automatic Osmometer (Precision Systems
Inc.). Urinary creatinine was determined using an enzym-
atic (creatininase) reaction and a Roche/Hitachi Modular
P Chemistry Analyzer. Urinary total I, Pb and Cd and
whole blood Pb and Cd were determined using inductively
coupled plasma dynamic reaction cell mass spectrometry
(ICP-DRC-MS) (PerkinElmer ELAN® 6100 DRCPlus or
ELAN® DRC II). Urinary As speciation was performed
using high performance liquid chromatography (HPLC)
coupled to ICP-DRC-MS. Combined urinary inorganic As
and methylated metabolites (AsIMM) was calculated as the
sum of arsenous acid (AsIII), arsenic acid (AsV), mono-
methylarsonic acid (MMA) and dimethylarsonic acid
(DMA) species, as this is the routine biomarker of As ex-
posure and does not incorporate non-toxic arsenobetaine.
Osmolality and UFR were both determined at the MEC
shortly after urine collection. The remaining measure-
ments were made after urine and blood samples had been
frozen at -20 °C and shipped to relevant laboratories
where they remained frozen until analysis to prevent evap-
oration and the inter-conversion of As species.
Urinary analyte adjustment calculations
Data were read into the R programming environment
[35] and partitioned into two subsets by simple random
sampling using the caret package [36]:
(1)Training dataset: 80 %, reserved for Araki’s b value
derivation.
(2)Testing dataset: 20 %, for applying and assessing
the performance of adjustment calculations.
The partition of 80:20 % was deemed suitable [37] and
was selected to (i) ensure sufficient training data were
available; (ii) retain a testing dataset of a size comparable
to that of a biomonitoring study in which these kinds of
adjustments may be employed and (iii) to preserve the
distribution of demographic and analytical variables be-
tween both datasets.
Urinary analyte excretion rates (ER, ng/hr) and body-
weight adjusted excretion rates (ERBW, ng/kg-hr) were
calculated using Eqs. 2 and 3, respectively [19]. Conven-
tional creatinine-adjusted analyte concentrations were
expressed in μg/g creatinine as follows:
Ccr‐adj ¼ Cvol=Ccr; ð6Þ
where Ccr is the specimen creatinine concentration in
grams per litre. Osmolality adjustment was performed
using an equation based on the Levine-Fahy specific
gravity adjustment [38] as follows:
Cosm‐adj ¼ Cvol  Osmref=Osmmeasð Þ; ð7Þ
where, for consistency with recent publications [19],
Osmref is the median osmolality (mOsm/kg) of training
data volunteers (734 mOsm/kg) and Osmmeas is that mea-
sured in the individual specimen. Araki’s b values were
extracted using an adaption of a previously published ap-
proach [22] which involved a simple numeric method.
Pearson correlation coefficients (rp) for criterion A and
criterion B were calculated from the training data for
values of Araki’s b from 0 to 1.5 at intervals of 0.01. Araki’s
b values that yielded optimum correlations for criterion A
(minimizing absolute value of rp) and separately for criter-
ion B (maximizing rp) were determined. Araki’s b values
were also derived on demographic subsets of specific age
groups and specific genders/ethnicities to identify patterns
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between groups. Optimum Araki’s b values were used to
perform Araki’s modified UFR adjustment (Eq. 5), hence-
forth referred to as UFRA and UFRB when adjusted using
optimum Araki’s b values for criteria A and B, respectively.
An R script has been provided in Additional file 1 to allow
other groups to derive Araki’s b values and perform hydra-
tion adjustments.
Statistical analyses
Due to the specific application of NHANES data in asses-
sing adjustment methods rather than making inferences of
biomonitoring measurements in the US population, sample
weights were not incorporated into analyses. Statistical tests
(and graphical presentations) were performed using R ver-
sion 3.0.0 (base package) [35]. Urinary and blood analyte
data were positively skewed and, therefore, geometric
means (GM) were calculated as opposed to arithmetic
means. For the same reason, Pearson correlations of urinary
analyte concentrations against UFR and blood analyte con-
centrations were calculated on natural log (ln) transformed
data with significance tests (p-values) and 95 % confidence
intervals (CI) using the ‘cor.test’ function. Pearson’s, as op-
posed to Spearman’s, correlation was selected to prevent
the loss of information that occurs when data are reduced
to ranks in the process of calculating Spearman’s correl-
ation. It was necessary to test the significance of the differ-
ence between correlations of, for example, urinary Pb with
blood Pb adjusted by different methods. These correlations
are not independent (because of the common variable,
blood Pb), so the Williams’s test [39] was performed using
the r.test function in the psych package [40]. Point density
contour lines were added to plots using two-dimensional
kernel density estimation in the MASS package [41].
Results
Exploratory analyses – training data
Inclusion of data for volunteers with the appropriate
demographic, examination and laboratory variables yielded
records for 3539 individuals. This was reduced to 2668 fol-
lowing the exclusion of volunteers with evidence of albu-
minuria, diabetes or CKD. A reduction to 2151 records
was made after excluding those with urinary analyte con-
centrations below analytical detection limits. These 2151
records were partitioned independently and at random
into a training dataset of 1723 records and a testing dataset
of 428 records reserved for independent adjustment com-
parisons. Study group characteristics, GMs and ranges of
creatinine osmolality, UFR, unadjusted urinary AsIMM, I,
Pb Cd and blood Pb and Cd of training and testing data-
sets are shown in Table 2, demonstrating the preservation
of characteristic and analyte distributions following the
partitioning of the data.
Training dataset log transformed urinary analytes, in-
cluding creatinine, showed (Fig. 1) significant (p < 0.001)
negative, log-linear relationships with UFR. This confirmed
previous findings [20]. The weak (Pb, Cd, AsIMM and I in
Fig. 1a-d) to moderate (creatinine, Fig. 1e) r2 values indi-
cated that the majority of variation in analyte concentra-
tions were not explained solely by UFR – this was most
pronounced for Cd and least pronounced for creatinine.
Large variations in urinary analyte concentration relative
to variations in UFR would be expected to result in criter-
ion A Araki’s b values >1, however the calculated Araki’s b
values for all urinary analytes were substantially <1, indi-
cating other controls on urinary analyte concentrations.
Notably, for As, the relationship between urinary AsIMM
and UFR was particularly impacted by the range of con-
centrations of DMA (Fig. 1c). It is noteworthy that the
Araki’s b value calculated from data for a single individual
[34] for Cd (Fig. 1f) (0.87) is substantially different from
that calculated data from multiple individuals (0.32).
Derivation of Araki’s b values – training data
Araki’s b values derived in the present study from pooled
NHANES data (single voids from multiple individuals)
by optimising criterion A or criterion B are presented in
Table 3 along with published values (where available)
from mean data derived previously [20, 21] (multiple voids
Table 2 Demographic characteristics and unadjusted analyte
geometric means (GM) and ranges for training and testing datasets
Training data Testing data
Demographic group, n (%)
All 1,723 428
Male 887 (51) 243 (57)
Female 836 (49) 185 (43)
Non-Hispanic white 841 (49) 216 (51)
Non-Hispanic black 489 (28) 116 (27)
Mexican American 393 (23) 96 (22)
6–11 years old 148 (8) 39 (9)
12–19 years old 268 (16) 63 (15)
20–39 years old 544 (32) 125 (29)
40–59 years old 461 (27) 120 (28)
>60 years old 302 (17) 81 (19)
Analytical measurement, GM (range)
Creatinine, g/L 1.1 (0.1–8) 1.1 (0.09–5.6)
UFR, mL/min 0.7 (0.03–34.5) 0.7 (0.06–5.5)
Osmolality, mOsm/kg 635 (91–1,394) 630 (84–1,350)
Urinary AsIMM, μg/L 6.3 (2.9–386) 6.4 (2.9–105)
Urinary I, μg/L 149 (8–15,651) 161 (16.9–9,322)
Urinary Pb, μg/L 0.5 (0.08–49.6) 0.5 (0.08–14.3)
Urinary Cd, μg/L 0.2 (0.04–6.2) 0.2 (0.04–4.8)
Blood Pb, μg/dL 1.1 (0.2–33.7) 1.1 (0.2–22)
Blood Cd, μg/L 0.3 (0.1–8.7) 0.3 (0.1–4)
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from single individuals). The criterion A optimised Araki’s
b values for Pb (0.38), Cd (0.32) and creatinine (0.52) were
all somewhat lower than values reported previously
[20, 21]. The criterion B optimised values for Pb (0.56)
and Cd (0.62) were closer to those published previously
[20, 21]. We note that the Araki’s b values derived to opti-
mise Criterion A agreed with the b values that describe
the slopes of the linear relationships shown in Fig. 1.
The sensitivity of Pearson correlations to model Araki’s
b values for criteria A (Pb, Cd, AsIMM, I) and B (Pb, Cd)
are illustrated in Fig. 2. In all cases, the criterion A and
criterion B optimised b values were all lower than the b
value (b = 1) implicit in conventional ER approaches and
were all better adjustments based on using Pearson correl-
ation as the metric.
Comparison of adjustment methods – testing data
The different adjustment methods were performed on an-
alyte concentrations and the resulting GM concentrations
and ranges are presented in Table 4. The performance of
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Fig. 1 Unadjusted urinary Pb (a), Cd (b), AsIMM (c), I (d) and creatinine (e) plotted against UFR (NHANES 2009–2012 (CDC, 2015) training data).
Multiple spot Cd measurements (Meharg et al., 2014) from a single volunteer are shown for comparison (f). Linear regression lines (blue) are
displayed with regression slopes and r2 values. *** denotes significance to p < 0.001. Point density contours were plotted using two-dimensional
kernel density estimation. In (c), the transition from green to red depicts increasing concentration of urinary dimethylarsonic acid (DMA)
Table 3 Araki’s b values derived for Pb, Cd, AsIMM and I in the
present study (NHANES 2009–2012 (CDC, 2015) training dataset)
compared with previously reported literature values
Analyte Araki’s b value
Criterion A
(UFR)
optimised
(present
study)
Criterion B
(Blood)
optimised
(present
study)
Araki et al.
(1986)a,c
Araki et al.
(1990)b,c
Pb 0.38 0.56 0.50 (0.45–0.91) 0.45 (0.39–0.54)
Cd 0.32 0.62 - 0.58 (0.42–0.66)
AsIMM 0.27 - - -
I 0.45 - - -
Creatinine 0.52 - 0.87 (0.67–1.01) 0.68 (0.58–0.75)
a Mean value of 10 subjects derived by linear regression
b Mean value of 4 time quadrants derived by linear regression
c Range of significant values in parentheses
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adjustment methods for urinary analyte concentrations
from the testing dataset were assessed against criterion A
(Pb, Cd, AsIMM and I) (Table 5) and criterion B (Pb and
Cd) (Table 6). The relative performance of these methods,
using Pb as an example, is also illustrated in Fig. 3 and
summarized below:
Criterion A
Pb: UFRA, Osmolality > Creatinine, UFRB >
Unadjusted > ERBW> ER
Cd: UFRA, Osmolality > Creatinine, UFRB >
Unadjusted > ERBW > ER
AsIMM: UFRA >Osmolality > Creatinine >
Unadjusted > ERBW > ER
I: UFRA > Osmolality > Creatinine > ERBW >
Unadjusted > ER
Criterion B
Pb: Osmolality ≥Creatinine ≥UFRB ≥UFRA > ER ≥
Unadjusted ≥ ERBW
Cd: Osmolality ≥Creatinine ≥UFRB ≥UFRA ≥ ER ≥
Unadjusted ≥ ERBW
Irrespective of whether criterion A or criterion B was
used to assess adjustment method performance, it was evi-
dent that UFRA, UFRB, creatinine and osmolality adjust-
ment methods all provided for a statistically significant
improvement relative to unadjusted analyte concentrations.
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Fig. 2 Sensitivity of Pearson correlations to Araki’s b value for NHANES 2009–2012 (CDC, 2015) training data for Pb (a), Cd (b), AsIMM (c) and I (d)
for criterion A (urinary analyte versus UFR, blue lines) and criterion B (urinary analyte versus blood analyte, red lines) with 95 % confidence intervals
(grey lines). Optimum criterion A (blue diamonds) and criterion B (red diamonds) Araki’s b values are displayed and, in the case of Pb and Cd, the
difference between these values is highlighted by double-headed arrows. Single-headed arrows illustrate the improvement in criterion A (decreasing
correlation) and criterion B (increasing correlation) correlations relative to the equivalent Araki’s b value implicit of ER
Table 4 Geometric means (GM) and ranges of urinary analytes following adjustment by various methods (testing dataset)
Urinary analyte,
GM (range)
Unadjusted,
μg/L
Creatinine-adjusted,
μg/g creatinine
Osmolality-adjusted,
μg/L, 734 mOsm/kg
ER, ng/hr ERBW,
ng/hr-kg
UFRA, μg/L,
UFR 1 mL/min
UFRB, μg/L,
UFR 1 mL/min
AsIMM 6.4 (2.9–105) 5.7 (1.3–55.6) 7.5 (2–82.4) 279 (18.5–3,921) 3.9 (0.2–64.8) 5.9 (2.2–92.4) -
I 161 (16.9–9,322) 143 (23.3–4,615) 188 (28.6–8,661) 7,024 (558–352,368) 97.5 (9.6–4,199) 140 (24.2–7,572) -
Pb 0.5 (0.08–14.3) 0.5 (0.06–16.1) 0.6 (0.06–17.5) 22.4 (0.8–1,042) 0.3 (0.008–13.9) 0.5 (0.04–15.4) 0.4 (0.03–15.9)
Cd 0.2 (0.04–4.8) 0.2 (0.03–2.6) 0.25 (0.03–4.9) 9.2 (0.5–97.5) 0.1 (0.006–1.5) 0.2 (0.02–3) 0.2 (0.02–2.2)
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Of these, osmolality adjustment was determined to be the
optimal adjustment method except for AsIMM and I for
which UFRA showed a marginally better performance. The
criterion A-based performance of osmolality and UFRA
adjustments were equally good for Pb and Cd. Indeed,
osmolality adjustment resulted in a weak (rp = 0.10) signifi-
cant (p < 0.05) correlation only in the case of osmolality ad-
justed AsIMM versus UFR. Creatinine adjustment, in
contrast, yielded significant positive correlations with UFR
for Pb (rp = 0.18), Cd (rp = 0.18) and As
IMM (rp = 0.32). Iod-
ine was an exception, with no significant correlation of cre-
atinine adjusted I concentrations against UFR.
Excretion rate adjustment methods (ER, ERBW) per-
formed worse than any of UFRA, UFRB, creatinine or
osmolality adjustments according to both criteria. Fur-
thermore, although ER and ERBW adjustments removed
observed negative correlations of unadjusted analyte
concentrations with UFR, they mostly resulted in posi-
tive correlations of an equal or greater magnitude. Ex-
cretion rate and ERBW adjustments thus performed no
better than implementing no adjustment at all, with the
sole exception of I, for which ERBW adjustment per-
formed marginally better (rp = 0.35 cf. -0.39).
An exercise was undertaken to derive Araki’s b values
for specific demographic groups of the data. The values
derived for specific genders and ethnicities and specific
age groups are presented in Table 7. Optimum Araki’s b
values were plotted against age group for Criterion A
(Fig. 4a) and Criterion B (Fig. 4b). Large differences in
optimum b values were observed between different gen-
ders and ethnicities across the range of analytes but no
obvious patterns were observed. For example, the
optimum Araki’s b values for non-Hispanic white males
were all lower than non-Hispanic white females for Cri-
terion A but higher for Criterion B. For non-Hispanic
black males, Araki’s b values were generally higher for
both Criteria than for females. There was a general in-
crease in optimum Araki’s b values with increasing age
group across the range of analytes for both Criteria. In
the case of Criterion A, for both gender/ethnicity and
age groups, we attributed the difference in b values to
the difference in group sizes. This is evident from the re-
sults presented in Table 7, where we also show the sig-
nificance of the relationship between UFR and analyte
concentrations. These slopes are synonymous with the
optimum Criterion A values presented in Table 7 and, in
smaller groups, some of the slopes are not significant.
Nevertheless, Criterion B is independent of the relation-
ship between UFR and analyte and, therefore, we chose
to pursue the investigation of age-specific Araki’s b values
for Criterion B. When UFRB adjustment was performed
using b values specific to the volunteers’ age groups, no
improvement in Criterion B correlations were observed
relative to adjustment with a single group-wide b value
(Pb: 0.73 versus 0.75; Cd: 0.60 versus 0.62).
Discussion
Osmolality and UFRA adjustment methods provided the
best or near best performance of the adjustment methods
tested using criterion A. Osmolality and creatinine adjusted
Table 5 Pearson correlations for performance Criterion A across the range of adjustment methods investigated for NHANES 2009–2012
(CDC, 2015) (testing dataset)
Adjustment
method
rp (95 % CI)
Pb Cd AsIMM I
Unadjusted -0.33*** (-0.41, -0.24) -0.25*** (-0.34, -0.26) -0.37*** (-0.45, -0.28) -0.39*** (-0.47, -0.31)
Creatinine 0.18*** (0.09, 0.27) b 0.18*** (0.09, 0.27) b 0.32*** (0.24-0.41) 0.09 (-0.001, 0.19)
Osmolality -0.001 (-0.10, 0.09) a 0.02 (-0.07, 0.12) a 0.10* (0.003-0.19) -0.09 (-0.18, 0.004)
ER 0.52*** (0.45, 0.59) 0.47*** (0.39, 0.54) 0.70*** (0.65, 0.74) 0.45*** (0.37, 052)
ERBW 0.43*** (0.35, 0.50) 0.42*** (0.34, 0.50) 0.60*** (0.53, 0.66) 0.35*** (0.26, 0.43)
UFRA 0.01 (-0.08, 0.11) a -0.01 (-0.10, 0.09) a -0.03 (-0.12, 0.07) -0.01 (-0.10, 0.09)
UFRB 0.18*** (0.09, 0.27) b 0.22*** (0.13, 0.31) b - -
Correlations were calculated on natural log transformed data. *** and * denote significance to p < 0.001 and <0.05, respectively. Bold font denotes the best
performing adjustment method for each analyte. Correlations share a letter when not significantly different from one another
Table 6 Pearson correlations for performance Criterion B across
the range of adjustment methods investigated for NHANES
2009–2012 (CDC, 2015) (testing dataset)
Adjustment
method
rp (95 % CI)
Pb Cd
Unadjusted 0.67 (0.61, 0.72) de 0.58 (0.51, 0.64) d
Creatinine 0.79 (0.75, 0.82) ab 0.65 (0.59, 0.70) ab
Osmolality 0.81 (0.78, 0.84) a 0.66 (0.60, 0.71) a
ER 0.69 (0.63,0.73) d 0.59 (0.52, 0.64) dc
ERBW 0.63 (0.57, 0.68) e 0.57 (0.50, 0.63) d
UFRA 0.74 (0.70, 0.78) c 0.62 (0.56, 0.67) bc
UFRB 0.75 (0.70, 0.79) bc 0.62 (0.56, 0.68) b
Correlations were calculated on natural log transformed data. All correlations
are significance to p < 0.001. Bold font denotes the best performing
adjustment method for each analyte. Correlations share a letter when not
significantly different from one another
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concentrations yielded the strongest correlations using
criterion B. In its nature, UFRA is tailored to optimise cri-
terion A performance, however, osmolality and creatinine
methods tended to perform better than Araki’s UFR-based
adjustment methods with respect to criterion B. This may
reflect greater uncertainties in volunteer reported times of
initial voids than in uncertainties in objectively measured
UFR surrogates such as osmolality or creatinine. The issue
of reliance on the accuracy of volunteer reported void
times when calculating UFR in NHANES has been raised
previously [19]. We note this as a limitation of the present
study, in that no efforts were made to refine UFR data or
quantify their accuracy.
Alternatively, differences in Araki’s b values for given
analytes, between individuals of different ages, genders
and ethnicities may partly account for deficiencies in
UFR based adjustments. Attempts were made to derive
Araki’s b values on demographic subsets of the training
dataset. Differences in optimum values were observed
between groups but this was possibly an artefact of dif-
ferent group sizes. When age-specific b values were im-
plemented to the adjustment of urinary Pb and Cd, no
significant improvements were observed in Criterion B
correlations. Future efforts should be made to derive
Araki’s b values for multiple individuals, collecting mul-
tiple voids at various states of hydration, to more closely
represent the relationship between analyte concentra-
tions and UFR, as illustrated in Fig. 1f. As proposed pre-
viously [23], these derivations should be made on
specific demographic groups to investigate whether the
relationship between analyte concentrations and UFR
vary in a characteristic manner, something which was
not achievable given the constraints of the data utilised
in the present study.
The finding that Araki’s b values calculated here by the
UFRA method were generally lower than those calculated
previously [20, 21], might give rise to questioning of the
validity of the UFRA based values. We therefore identify a
potential flaw in the validity of criterion A when using the
present dataset. As discussed, it was not possible to derive
Araki’s b values in the conventional manner using the
NHANES dataset. This requires multiple voids from
single volunteers at different hydration states, circum-
stances under which the ‘true’ relationship between UFR
and analyte concentration is observed due to the
relatively constant internal dose of a given analyte, for a
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single individual, over the timescale investigated.
NHANES data consist of single voids from multiple indi-
viduals with greater inter-individual ranges of internal
doses which have the potential to alter the observed slope
(b value). Under circumstances where the standard
deviation of the distribution of internal dose is consider-
ably bigger than that of the distribution of UFR for the
studied population, the calculated Araki’s b value may be
positively biased. This in-turn determines the optimum
value for criterion A - the b value that describes the slope
between UFR and analyte – evident in the agreement
between the b values that describe the slopes presented in
Fig. 1 and those derived using the numeric method. This
is further illustrated by the difference between criteria A
and B optimum values for Pb and Cd (Fig. 2a and b), the
criterion B optimums could be considered more robust
for the NHANES dataset used here as they are independ-
ent of UFR. We note, however, that this paper does not
purport to suggest specific Araki’s b values for application
elsewhere, but is successful in reiterating proof of concept
of their necessary implementation to remove hydration
variation from spot analyte concentrations and, in doing
so (Fig. 2a and b), better reflect internal dose.
Our findings reiterate the analyte-specific nature of hy-
dration adjustment, exemplified by the difference in cri-
teria A correlations between creatinine adjusted AsIMM
and I. Creatinine adjusted I concentrations yielded no
significant correlation with UFR, whereas creatinine ad-
justed AsIMM concentrations were more strongly corre-
lated with UFR than I, Pb and Cd. Inspection of Fig. 1c
indicates differing relationships with UFR of urinary
AsIMM for high-DMA and low-DMA samples – this
suggests that the biochemistry of different species of the
same element (and different elements) influence Araki’s
b values.
As noted previously [19], for studies outside the
NHANES framework or similar population-scale bio-
monitoring designs, the collection of UFRs may provide
additional value providing that accurate recordings of
time and volume are obtained. It is recognised that this
Table 7 Araki’s b values derived for AsIMM, I, Pb and Cd on specific demographic sub-groups of the present study group (training dataset)
Demographic group n Optimum Araki’s b value
Criterion A Criterion A Criterion A Criterion A Criterion B Criterion B
AsIMM I Pb Cd Pb Cd
Non-Hispanic white male 416 0.28*** 0.50*** 0.42*** 0.31*** 0.68 0.96
Non-Hispanic white female 425 0.33*** 0.58*** 0.50*** 0.46*** 0.54 0.63
Non-Hispanic black male 265 0.27*** 0.51*** 0.46*** 0.29*** 0.56 0.53
Non-Hispanic black female 224 0.24*** 0.32*** 0.24*** 0.34*** 0.44 0.53
Mexican American male 206 0.11* 0.30*** 0.10 0.02 0.26 0.18
Mexican American female 187 0.34*** 0.40*** 0.46*** 0.37*** 0.58 0.56
6–11 years old 148 0.14* 0.28*** 0.38*** 0.08 0.10 1.38
12–19 years old 268 0.22*** 0.34*** 0.23*** 0.21*** 0.38 0.24
20–39 years old 544 0.27*** 0.41*** 0.39*** 0.46*** 0.58 0.82
40–59 years old 461 0.36*** 0.48*** 0.46*** 0.58*** 0.50 0.61
>60 years old 302 0.33*** 0.55*** 0.60*** 0.66*** 0.70 0.79
In the case of Criterion A, *** and * denote the significance of the relevant UFR-analyte regression slopes to p < 0.001 and 0.05, respectively
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may not be logistically feasible for all studies and surro-
gates such as creatinine and osmolality are attractive al-
ternatives. Modifications of these surrogate based
adjustments have also been explored [22, 23, 42] using
methodologies based on the work of Araki et al. (1986).
These approaches, such as modified SG [23] or modified
creatinine [25] adjustment, were not addressed in the
present study and further exploration of such alterna-
tives may prove valuable for studies that are restricted in
their ability to directly measure UFR, particularly in low-
budget circumstances or developing countries. Similarly,
measurements of additional urinary constituents that are
indicative of medical conditions, such as glucose, pro-
tein, ketones and bilirubin, could have provided add-
itional data exclusion criteria had they been available to
us. A comparison of the performance of different adjust-
ment methods between volunteers with and without the
presence of such analytes, and the medical conditions
that were available as exclusion criteria (e.g. CKD and
diabetes) will make for an important matter of further
research.
The implications of the findings made in this investiga-
tion, and the questions that remain unanswered, have im-
plications for environmental and epidemiological studies
using urinary biomonitoring to assess human exposures
and investigate the dose-response relationships between
environmental chemicals and health end-points. The dif-
ferences in biomarker levels yielded by different adjust-
ment methods is evident (Table 4). This impacts the
interpretation of results when making comparisons to
existing guidance or reference values. Furthermore, it im-
pacts the derivation of reference values themselves. For
example, a large and much needed body of work has been
undertaken to derive biomonitoring equivalents to be used
in comparison with various urinary biomarkers [43]. Some
derivations have utilised creatinine adjustment, which may
have limited their applicability to studies using alternative
adjustment methods, or other studies using creatinine ad-
justment with different demographic structures. This
problem also extends to studies that explore relationships
between urinary analyte concentrations and health
outcomes- a widely used application of NHANES data
[44–46]. A robust, standardised framework of urinary
hydration adjustment is warranted to ensure the val-
idity and sensitivity of such analyses.
Conclusions
We have demonstrated for the urinary analytes studied
(Pb; Cd; AsIMM and I), and the adjustment methods con-
sidered (osmolality; creatinine; excretion rate (ER); body
weight adjusted excretion rate (ERBW); urinary flow rate
adjustment with Araki’s b optimised to minimise correl-
ation with urinary flow rate (UFRA) and urinary flow
rate adjustment with Araki’s b optimised to maximise
correlation with blood analyte concentrations (UFRB):
(i) Osmolality consistently performs as the best or near
best adjustment method against two performance
criteria: minimum correlation of adjusted urinary
analyte concentration with UFR; maximum
correlation of adjusted urinary analyte concentration
with blood analyte concentration.
(ii) The method of Araki et al. (1986, 1990) for
objectively determining Araki’s b values to adjust
urinary analyte concentrations also performs well,
but is limited by the requirement for accurately
determined UFR data and age/gender/ethnicity
specific b values.
(iii)Creatinine adjustment methods may be suitable for
some analytes (e.g. I) that have similar b values to
creatinine, but can otherwise result in significant
biases.
(iv) ER and ERBW based adjustment methods are
shown here to overcompensate for UFR and
invariable performed worse than osmolality,
creatinine, UFRA, UFRB and often worse than
unadjusted concentrations.
Thus, we demonstrate that conventional application of
UFR is limiting the full potential of this metric. The
under-performance of both ER and ERBW in relation to
two independent performance criteria support previous
findings [20, 21] that using UFR to calculate excretion
rates in the conventional manner propagates inaccurate
results. The inclusion of Araki’s b values into adjustment
calculations was demonstrated to significantly improve
the performance of UFR adjustment for both criteria
relative to ER and ERBW adjustments.
The derivation of specific Araki’s b values requires sub-
stantial further work by collecting multiple voids from the
same individuals. By compiling a range of Araki’s b values
for a range of analytes and demographic characteristics,
their determining factors can be assessed, enabling the de-
velopment of more sophisticated framework for urinary
biomarker adjustment. Finally, additional constraints on
the interpretation of urinary biomarker concentrations
need addressing, such as time of sampling relative to ex-
posure [1], which hydration adjustment cannot overcome.
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